Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. (Q47860399)

From Wikidata

Jump to navigation Jump to search

scientific article published on 14 January 2008

Language	Label	Description	Also known as
English	Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers.	scientific article published on 14 January 2008

Statements

scholarly article

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. (English)

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Pierre Vandepapelière

1

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

Yves Horsmans

2

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

Philippe Moris

3

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

Marcelle Van Mechelen

4

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

Michel Janssens

5

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

Marguerite Koutsoukos

6

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

Pascale Van Belle

7

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

Frédéric Clement

8

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

Emmanuel Hanon

9

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

Martine Wettendorff

10

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

Nathalie Garçon

11

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

Geert Leroux-Roels

12

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

language of work or name

0 references

publication date

14 January 2008

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

26

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

10

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

1375-1386

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

Vaccines against intracellular infections requiring cellular immunity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Progress on new vaccine strategies against chronic viral infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Immunological foundations to the quest for new vaccine adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Strategies for designing vaccines eliciting Th1 responses in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Glycoprotein-D–Adjuvant Vaccine to Prevent Genital Herpes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Targeting the innate immune response with improved vaccine adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

The influence of adjuvant on the therapeutic efficacy of a recombinant genital herpes vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Towards the rational design of Th1 adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Vaccine adjuvants revisited

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Smart adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Recent advances in the discovery and delivery of vaccine adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Cooperation of Toll-like receptor signals in innate immune defence

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

A human homologue of the Drosophila Toll protein signals activation of adaptive immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Toll-like receptors: critical proteins linking innate and acquired immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Toll-like receptor 4, but not toll-like receptor 2, is a signaling receptor for Escherichia and Salmonella lipopolysaccharides.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Cutting edge: repurification of lipopolysaccharide eliminates signaling through both human and murine toll-like receptor 2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Mechanisms of phagocytosis in macrophages

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Toll-like receptors control activation of adaptive immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Role of Toll-like receptors in pathogen recognition.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

QS-21: a water-soluble triterpene glycoside adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Safety, tolerability and immunogenicity of new formulations of the Plasmodium falciparum malaria peptide vaccine SPf66 combined with the immunological adjuvant QS-21.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterization of CD8+-T-cell epitopes recognized.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS,S/AS02, in semi-immune adults in The Gambia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Development and pre-clinical analysis of a Plasmodium falciparum Merozoite Surface Protein-1(42) malaria vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Therapeutic potential of Toll-like receptor 9 activation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

CpG motifs in bacterial DNA and their immune effects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Detection of antigen-specific T cell cytokine expression in whole blood by flow cytometry.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

T cell mediated immunity to Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

T cell responses to pre-erythrocytic stages of malaria: role in protection and vaccine development against pre-erythrocytic stages

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Therapeutic vaccination against chronic viral infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Therapeutic vaccines for chronic infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Progressive differentiation and selection of the fittest in the immune response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

The immunobiology of the TLR9 subfamily

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Mucosal immunity in the female genital tract

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Systemic and secretory humoral immunity in the normal human vaginal tract

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Adjuvants for human vaccines--current status, problems and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Vaccination and autoimmune disease: what is the evidence?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

Characterization of a nontoxic monophosphoryl lipid A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

based on heuristic

inferred from DOI database lookup

A study of the cellular and molecular mediators of the adjuvant action of a nontoxic monophosphoryl lipid A.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.038

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2007.12.038

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

1 reference

Europe PubMed Central

6 February 2018

http://europepmc.org/abstract/MED/18272264

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47860399&oldid=1540170845"